
Dominic Schmidt
General partner at London's Advent Life Sciences since 2022; formerly a partner at Syncona.
Last refreshed: 14 November 2026
Can T-cell receptors crack solid tumours where antibody engagers stalled?
Timeline for Dominic Schmidt
T-Therapeutics raises $133m in Series B
UK Startups and InnovationBackground
Dominic Schmidt is a general partner at Advent Life Sciences, a London life-sciences venture investor, which appointed him in 2022. He spent eight years before that as a partner in the investment team at Syncona.
Advent co-led T-Therapeutics' $133m Series B with the British Business Bank in November 2026. Schmidt said T-cell engagers have worked in blood cancers but "have been held back in solid tumours", which he told BioPharma Dive came down to "the lack of appropriate targets". T-Therapeutics' receptors read protein fragments from inside cells, reaching targets antibodies cannot.
Advent lists his board roles as including Amphista Therapeutics, AviadoBio and Pheno Therapeutics.
Who is Dominic Schmidt of Advent Life Sciences?
Who led T-Therapeutics' Series B?
Why have T-cell engagers struggled in solid tumours?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.